|
Accueil > Actualité
AstraZeneca: FDA approves Fasenra for severe asthma.
(CercleFinance.com) - AstraZeneca said on Wednesday that the US Food and Drug Administration (FDA) has approved Fasenra for the add-on maintenance treatment of patients with severe asthma.
The biopharmaceutical firm, which is in the midst of a "pipeline-driven transformation," said that the FDA's approval is based on results from a phase III trial showing up to a 51% reduction in asthma exacerbation versus placebo. Last week, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) also adopted a positive opinion, recommending the drug's marketing authorisation. Copyright (c) 2017 CercleFinance.com. All rights reserved. |
19/04/2024 08:57
Veoliade fortes ambitions de croissance aux Etats-Unis 19/04/2024 08:42 Pluxeerelèvement des objectifs annuels 19/04/2024 08:18 Sodexohausse de 46% du résultat net ajusté au 1er semestre 19/04/2024 08:00 Spieacquisition d'ICG Group finalisée en Allemagne 19/04/2024 07:42 Argandividende versé à près de 28% en actions 19/04/2024 07:25 Mercialyshausse de 4,5% des loyers au 1er trimestre Tous les articles sociétés |
